Ten different samples of lyophilized plasma and two of liquid urine were distributed during two years to 26 laboratories performing quantitative amino acid analyses in a scheme designed to provide external quality assessment.
Laboratories performing such analyses were approached, and those expressing an interest were recruited into the scheme. Here we report the establishment of this scheme and the results obtained from its operation during two years.
MaterIals and Methods

Participants
In 1985, laboratories in the United Kingdom believed to be performing amino acid analyses in medically related applications were identified through personal contact or from manufacturers ' lists of users and invited to participate in an external quality-assurance scheme. Each was sent a questionnaire requesting demographic information about laboratories, applications of their analyses, workload, methods (including sample preparation, standardization, quality control, and data processing), and their qualityassessment requirements in terms of the type and frequency of sample, reporting, and scoring formats. Interested laboratories were sent a trial sample for analysis (sample no. 1/85), and the results of the survey were returned to them. They were then invited to register for the receipt of samples on a regular basis. Twenty-six laboratories (all in the British Isles) registered for the scheme; 11 were in teaching, eight in district general, and six in children's hospitals; one participant was a microbiological research establishment.
The applications of the analyzers were described by participants as follows (some participants reported more than one application): diagnosis and monitoring of inborn errors of metabolism (n = 23), renal and metabolic research (n = 2), and analysis of growth media (n = 1). Secondary applications listed were unspecified research (n = 8), parenteral nutritionmonitoring and research (n = 6), renal investigations (n = 3), nutritional investigations and research (n = 3), inherited metabolic diseases (n = 2), and metabolic studies, liver investigations, and quality control of bacteriological culture media (1 each). Participants reported annual workloads of between 50 and 1250 analyses. Table 1 lists analytical methods, manufacturers, and models of analyzer.
Methods
Most participants used automated ion-exchange chromatography (AlE) with colorimetric nmhydrin detection (5). Four participants used AlE with fluorimetric detection after reacting amino acids with ophthalaldehyde (OPA) (6) . All ME methods involved use of lithium citrate buffers. Four participants used "high-performance" liquid chromatography (HPLC) with pre-column derivatization, three using OPA (7) and one 5-dimethylainino-1-naphthalene sulfonyl (DAN8YL) (8) to form deriva- tives. Ten participants reported automated data processing, with use of various types of computing integrator, six described manual peak identification and measurement, and 11 reported combined methods (usually visual peak identification, followed by automated integration of the identified peaks).
Reagents
Amino acids (chromatographically pure) were obtained from BDH Ltd., Poole, U.K. All other reagents were of "ANALArt" grade, from the same supplier.
Lyophilized plasma samples. These were obtained in sealed, rubber-capped vials (5-or 10-mL) from the U.K.
External
Quality Assessment Scheme, Queen Elizabeth Medical Centre, Birmingham, U.K., and from Wellcome Diagnostics, Dartford, U.K., and were surplus to their requirements for general clinical chemistry EQA schemes. One of these samples (no. 1/85), pooled human plasma from blood donated for transfusion, was distributed before warnings concerning IIIV infection were publicized. Thereafter all lyophilized plasma samples distributed were of bovine origin. For some distributions, participants were instructed to reconstitute the samples with the appropriate volume of distilled or de-ionized water. However, to introduce sufficient variation into the amino acid proffle, some samples were accompanied by an aqueous reconstituting solution of amino acids for addition to the lyophilized plasma.
Reconstituting solutions. These were made by dissolving weighed amounts of pure, commercially available amino acids in de-ionized water, adjusting the solution to pH 2 with hydrochloric acid (6 mol/L), and ifitering it through a cellulose acetate filter of 4.5-pm pore size. Aliquots of this solution, in volumes slightly in excess of those needed to reconstitute the plasma, were dispensed into screw-capped vials and sealed with waxed film. The fact that reconstituted volumes were 10 mL in 1986 and 5 mL in 1987 was fortuitous and due to the types of lyophilized materials available.
Urine samples. Urine collections from adult laboratory staff were adjusted to pH 2 with hydrochloric acid (6 mol/L) and autoclaved in bulk at 121 #{176}C for 15 mm. After cooling, we added weighed amounts of pure amino acids and preservative (100 mg of thimerosal per liter of urine) and mixed well. The sample was then ifitered by the same method as the reconstituting solution (above), and 2.5-mL aliquots were dispensed into screw-capped vials. Table 2 gives detailsof the samples and reconstituting solutions.
Dispatch
of samples. Samples were sealed in plastic wallets and packed into boxes with absorbent wadding. A standardized report form (Figure 1, left) Autoclaved urine with added valine, leucine, and isoleucine
6/87 WellcomeBCA1
Amino acid(s) added Aboutnormal, but increased glutamic acid and decreased glutarnine. 10 About normal but glutamine decreased. 10
Above-normal branched-chain amino acids; othersabout normal.
10
Increasedconcnsof phenylalanine,leucine, and glutamicacid; decreasedglutamine; othersabout normal. 10 Generallylowto normalconcns.
Increased ornithine,decreasedglutamine, otherslow to normal. 10 increased glycine, decreased glutamine, others low to normal. 5 Generallyvery low concns. 5
Abnormal profile, generally low concns, but valine, leucine, omithine, and isoleucine increased.
2.5'
Increased glycine, others moderately increased.
5
Increased citrulline; glutamine and alanine moderately increased; others low.
2.5
Increased glycine, isoleucine, leucine, and valine;othersmoderatelyincreased.
d Humanmaterial;all others bovine,a Uquid urine; all others lyophilized plasma. 'Volume dispensed.
were given a date by which reports had to be returned, a date that allowed at least two full working weeks for analyses to be completed. Cakulation of results. Statistical summaries and performance scores were calculated from returned results, and reportswere generated with a BBC "B" microcomputer (Acorn Computers Ltd., Cambridge, U.K.) and specifically written software. Results from participants were treated as is conventional for EQA schemes (9). The mean, standard deviation (SD), and coefficient of variation (CV) were calculated for each amino acid.4 Each individual result from a 4x, result returned (imo1JL); 1, mean; n, no. of results received for each amino acid reported by different participants for each sample; N, no. of results received for different amino acids reported by each participant for each sample; m, no. of returns for which results are included in the calculations; ASD, delta standard deviation of result, (x -1)/SD I; B, percentage bias, 100(x -1)/I; RMS, root mean participant was then compared with the mean for that amino acid and the absolute difference between them was expressed in delta standard deviation (zSD). If ASD exceeded 3, the result was eliminated as an outlier. The mean, SD, and CV were then recalculated for the remaining results, which were compared with the new trimmed mean to calculate revised ASDs. This process was continued until no more outliers were detected. In the final cycle of calculation, iSDs (including those of the outliers) and percentage biases (B) were calculated and recorded. These procedures were repeated for each amino acid for which a result had been reported by a participant.
To estimate the performance of each participant for all the amino acids in a particular sample, we calculated the 
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PCcOPSTITh1t P05 #{149} P1 AT 50014 TEPCRAT%E. root mean square (RMS) of the iSDs and the arithmetic mean of the biases (mean percentage bias, MB) from the results of all amino acids reported. The calculation of RMS was appropriate for the SDs and CVs because these were derived from the sums of squares of the results. It became apparent from the results of the trial distribution that, to avoid gross distortion of the statistical summaries and the allocation of inappropriate scores, we had to set arbitrary limitations on the results. Thus, SD and B were set at maxima of 3 and 100%, respectively, and results below the minimum of 10 returned results or a mean of 20 .&mo1/L for any amino acid in a distribution were excluded. Results from amino acids that fell below these latter criteria also were excluded from calculations for assessing the performance of laboratories and the assay of individual amino acids. These exclusions were applied both to the performance scores returned to participants for each sample and to the summarized results in this report. As a further indicationof performance, each participant was given a ranking for their RMS of ISD and MB after comparison with the results from all other participants for that particular sample. Participants were asked to record the amounts detectedfor a list of amino acids most commonly found in physiological fluids, but they were also invitedto include any additional unlistedamino acids detected. Figure 1 (right) shows a typical report of a participant's results.
At the end of each quality-assessment
period (one year, six samples),participants receiveda summary of their performance over that year. This included an annual RMS of SDs and annual mean bias for each amino acid reported. Overall RMS and MB for all amino acids from all samples for which results were reported were calculated, and a ranking score was obtained so that each participant received a comprehensive summary of their performance for the year.
Results
Of'the 24 laboratories sent the trial sample (no. scheme were analyzed in two ways. Estimates of the varianceof individual amino acids were obtainedfrom the RMS of the CVs that were calculated after each of the 12 distributions, and these are shown in Table 3 . Interlaboratory comparisons, on the other hand, were obtained from the RMS of the score(SD) of each result returned ( Table  1 ). The latter method was also used when we assessed groups of participants-for example, to compare methods. Upon request, we will supply full statistical summaries for each of the samples distributed.
As an additional means of stunmarizing performance, the total numbers of outlying results attributable to individual participants and to particular amino acids were noted. There was no obvious association between the number of outlier values detected and the RMS of CVs of individual amino acids, but laboratories with better performance, as assessed by RMS of SDs, tended to produce fewer outliers (Table 1) .
Uncommon amino acids and other compounds not listed on the reporting sheet but reported by some participants were as follows (number of occasions reported): a-aminon-butyric (68), 3-methylhistidine (37), 1-methylhistidine (34), #{225}sparagine (29), hydroxyproline (24), ethanolamine (19), a-aminoadipic (12), phosphoserine (8), /3-aminoisobutyric (8), allo-isoleucine (8), homocystine (5), cystathionine (5), carnosine (5), homocitrulline (3), 'y-aminobutyric
, methionine sulfone (2), hydroxylysine (2), and /3-alanine (1). We added allo-isoleucine to one sample. /3-Aminoisobutyric acid, homocitrulline, methionine sulfone, and hydroxylysine were reported in urine samples only.
Discussion
The pre-scheme questionnaire provided demographic and analytical information about participants and allowed them to indicate their EQA preferences. The consensus that emerged, on which the scheme was based, was that most samples should be lyophilized plasma and that these should be distributed six to 12 times a year,that participants should be able to report the concentrations of any amino acids detected in the samples, and that they should receive reports giving statistical summaries of results and assessments of their own performance in terms of standard deviations from the mean. Some participants also requested a report of the bias (%) of their results and use of a devised scoring system. The scheme was designed substantially to comply with these requirements.
Most participants gave the diagnosis and monitoring of inherited metabolic diseases as their primary reason for performing quantitative analyses for amino acids. Participants in teaching or children's hospitals ordinarily provided a reference service for general hospitals, some of which would be performing qualitative screening tests for these disorders.
Eight of the participants were themselves district general hospitals, and the operation of amino acid analyzers in such sites resulted from particular local interest and expertise. The wide range in the number of amino acid analyses performed per annum by participants reflects the provision of either local or reference services.
Most of the laboratories in the British Isles performing quantitative analyses for amino, acids in clinical situations were included in the scheme. The small number of participants, as compared with the numbers ordinarily found in Table 3 . Summarized Results from All Samples Distributed national EQA schemes, reflects the specialized nature of these analyses. However, the relatively large number of "analytes" (individual amino acids reported) enabled comparisons to be made of imprecision between laboratories and between individual amino acids when results were combined across 12 distributions over two years.
IFCC recommendations speci1' such desirable properties for quality-assurance materials as similarity to patients' specimens, stability, and homogeneity (10). These considerations, in conjunction with the replies from the questionnaire, mandated that plasma should be the commonest sample to be distributed but that urine or aqueous specimens should also be considered. Although in some EQA schemes liquid plasma samples are used, the known chemical or bacteriological instability of some amino acids (11) limits the usefulness of such material. Lyophilized plasma samples were chosen for their stability but, when samples from various sources were examined, it became apparent that (a) processing had generally decreased the amino acid concentrations below those usually found in human plasma, (b) the concentrations of some amino acids (e.g., glutamine) were greatly decreased, and (c) the variation in the amino acid profile of lyophilized plasma samples from various sources was insufficient to represent the range of patterns found in pathological samples. To overcome these deficiencies, we distributed some lyophilized samples with reconstituting solutions that contained added amino acids. However, the use of these solutions did not contribute to the variability of results, because the RMS of CVs of samples reconstituted with them (25.9%) was no greater than that of samples reconstituted with water (26.0%). For 11 of the 12 samples distributed, the proportion of participants making returns varied between 77% and 96%. The response to sample no. 3/87, the first liquid urine to be distributed, was 65%, the response for the second urine sample (no. 5/87) was 81%. The mean response for all samples over the two years was 83%.
The number of returns made at each distribution (between 17 and 24) was sufficient for statistics and performance scores to be calculated for most of the common amino acids. The RMS of the CVs of all the common amino acids measured over all 12 distributions was 27% (Table 3 ). This result was obtained after outlying values had been removed at the calculation of each distribution and the exclusion of CVs when fewer than 10 results were returned for a sample or the trimmed mean for an amino acid was <20 moI/L (see Cakulation of results). Williams (2) obmined an arithmetic mean CV of 23% for amino acids measured by four laboratories in a single distribution of bovine plasma. lithe results in that report are recalculated as the RMS of the CVs, the CV becomes 28%. Thus two surveys of widely differing design obtained similar estimates of overall variation in the measurement of amino acids. In the present survey, the RMS of the CVs for the two urine samples exceeded that of the lyophilized plasma samples (Table 3 ), though the difference was not significant by the Mann-Whitney U test. Liquid urine samples can be expected to be less stable than lyophilized plasma during distribution despite the precautions taken, but greater variability of results might also be due to the greater number of peaks obtained in a urine chromatogram and hence the increased potential for interference with peak measurement.
The wide variation in the RMS of the CVs for individual amino acids (Table 3 ), in part due to differences in their concentrations in the samples, also demonstrates the extent of their analytical individuality.
In quantitative chromatography, adequate peak shape and resolution are prerequisites of accurate peak measurement; however, other factors can be examined that could have contributed to the poor performance of analyses for specific amino acids.
Amino Acids
Methionine. None of the samples distributed was supplemented with methionine, and its endogenous content was generally low. Consequently, results from only five returns were included in the summary.
In addition, sample no. 2/86 contained allo-isoleucine, which was mistaken for methionine by some participants and resulted in a particularly high CV for methionine. If, however, the results for methionine in sample no. 2/86 are omitted, the RMS of the CVs decreases to 43%, which is still higher than for any other amino acid.
Tryptophan.
This was present at concentrations generally within or below concentrations to be expected in normal human plasma. Some proportion of tryptophan, which can vary with sample conditions such as pH, is bound to albumin and may be lost during sample preparation (11). In some chromatographic systems, this amino acid gives a relatively broad, shallow peak, and its retention times may alter if conditions are not held stable.
Histidine. The relatively poor performance of analysis of this amino acid is not readily explained. Inclusion of 1-or 3-methylhistidine with the histidine peak would cause some variability. One participant reported the presence of an unidentified substance interfering with the histidine peak in some materials.
Taurine.
This was reported less frequently by participants than most of the other common amino acids, probably due to its unimportance in the investigation of inherited metabolic diseases and its early elution in the chromatogram.
Proline.
This imino acid can be difficult to quantify, owing to its limited chromogenicity with ninhydrin and the need to measure the product at 440 ma. Proline and hydroxyproline were not reported by participants using HPLC.
Ornithine, lysine, arginine. The imprecision with which these basic amino acids was measured was similar (between 26% and 28%, Table 3 ). Several amino acids for which detection and quantification were poor were located in the basic area of the chromatogram.
Glutamine. This amino acid is readily deaminated to glutamate and ammonia during sample handling, chromatography, or storage (11). Pre-analytical factors are therefore likely to contribute to its observed variability.
Others. Determination of the remaining common amino acids was better overall than for those discussed above. Various factors might have been responsible for this, including higher concentrations in the distributed material (e.g., glycine); less-troublesome chromatography, exemplifled by a sharp, symmetrical peak shape with freedom from interference; clinical relevance, which would lead to more common measurement (e.g., phenylalanine); and possibly proximity to an internal standard within the chromatogram. This could be particularly true for amino acidseluted near norleucine, the most commonly used internal standard. Amino acids with better performance were generally from the acidic to neutral regions of the chromatogram. Glutathione, which co-elutes with aspartate in some systems, can be released from erythrocytes during plasma processing (11), so that mean concentrations of aspartate in some samples may be overestimated. Amino acids with disulfide bonds-e.g., cystine and homocystine-become bound to protein unless plasma samples are promptly deproteinized after collection (11). Cystine concentrations in the lyophilized plasma samples were low and were frequently reported as zero by participants; therefore, this amino acid has been omitted from the summarized results. Probably the blood collection and processing of the lyophilized samples resulted in the binding of free cystine. The measured concentrations of cystine in the distributed samples was method-dependent, particularly high results being obtained by HPLC (7). In HPLC, the sample is pre-treated with iodoacetate to form Scarboxymethylcystine, which is then converted to a fluorescentderivative with o-phthalaldehyde and mercaptoethanol (12). Cooper et al. (13) suggested that, in conventional methods of protein precipitation for amino acid analysis, variable amounts of free cystine are removed from plasma and that one must use HPLC to determine the true concentration.
Problems with other individual amino acids became
No. labs
RMS of SD
The need to precipitate plasma proteins without delay when one needs to know cystine or homocystine concentrations is well-known (11), but the gross differences obtained by Cooper et al. (13) between HPLC and AlE methods may be due not only to deficiencies in the latter technique but also to the nature of the sample pretreatment for HPLC.
In addition to the 22 common amino acids, participants were invited to report unlisted amino acids and other compounds detected. Returns for these substances were usually sporadic, in part because of the absence from, or low concentrations in, the distributed materials, but also because participants differed in the importance they attached to minor peaks in the chromatograms.
Data Analysis
The data from returns are also examined to compare methods of analysis, types of analyzer used, and the type of participating laboratory. Although none of the differences was significant (P <0.05) when tested by the MannWhitney U test or the Kruskall-Wallis one-way analysis of variance, this could be due to the inhomogeneous nature of the data. Thus we present the results as observed trends.
Assessment based on RMS of ASDs showed that of the three method groups recognized in the amino acid EQA scheme, AlE with ninhydrin detection (used by more than two-thirds of the participants) appeared to give the best performance, although as noted above this was not a statistically significant difference (Table 4) . Because the target values in this analysis are the consensus all-method trimmed means, one must consider the possibility that participants using minority methods were penalized. No such effect was apparent in the data, however, except in the example of cystine discussed above. suggests that the expertise of participants was at least as important a factor of performance as the choice of method. Apparent differences between makes of analyzer are also presented, but these were not significant when tested by analysis of variance. In addition, as noted above, results from groups containing few participants could be biased by aptitude as much as by choice of instrumentation. Differences between the various types of hospital laboratory were small and nonsignificant:
RMS of SDs were 1.01 (n = 7) for children's hospitals, 1.07 (n = 11) for teaching hospitals, and 1.09 (n = 8) for general hospitals. Laboratories that acted as reference centers for amino acid analyses (Table 1) appeared to perform better overall than those that did not [RMS of the SDs 0.98 (n =13) and 1.15 (n = 14), respectively], but the differences were not significant by MannWhitney U test. The single nonhospital laboratory, which scored 0.88 on this basis, returned only three results during the period in question because it entered the scheme late.
An analysis of rejected outlying results indicated that such outliers did not correspond with the performance of individual amino acids when assessed by RMS of the CVs (Table 3 ). This result might be expected, because trimming to ±3 SD should, on average, produce a similar number of outlying values. On the other hand, the number of outlying results obtained by individual participants was related to the RMS of their SD (Table 1) . A relationship between the number of outliers removed and the RMS of SD was also sustained when we compared methods, analyzers, and institutions.
We could not demonstrate an improvement in the performance of amino acid analyses by participants over the first two years of the EQA scheme, either by examination of the RMS of the CVs or from the number of outliers removed from sample to sample. The subjective impression, however, is that in the second year of operation fewer outliers were attributable to peak misidentification. There was no formal procedure for follow-up of participants with poor performance, the onus for improvement being left to individual laboratories.
On the other hand, informal discussions with participants on both general and specific problems were frequent, and sources of advice were suggested.
The overall RMS of the CVs (27%) and the range of CVs for individual amino acids revealed considerable scope for improvement in the performance of the analyses. It has been suspected for some time that the measurement of amino acids in physiological fluids is not very reliable, owing to the relative instability and complexity of these samples as compared with protein hydrolysates (2, 14). Ambler (15) examined the several stages of amino acid analysis that might be susceptible to error, including sample deproteinization.
In their survey of four laboratories, however, Williams et al. (3) found that sample deproteithzation centrally by the organizing laboratory did not reduce the variability of results.
Examination
of data from quality-assurance surveys is one method for determining whether goals for analytical performance are being met (16). If applied as a sample exercise to the amino acid that performed best in the scheme (glycine), the one that performed worst (methionine), and one of obvious clinical importance (phenylalanine), it becomes apparent that performance goals are not being satisfied. Setting these goals requires knowledge of intra-and interindividual ("biological") variation (16), but the amount of such information for amino acids is limited (17) and reference intervals (11) have to be used as a first approximation.
One definition for an analytical goal is that the analytical CV should be equal to or less than half the biological CV (16); if reference intervals are used, the desired analytical CV for the above three amino acids should be 9.4%, .9.5%, and 7.4%, respectively.
The actual analytical
CVs obtained for them in the EQA scheme (Table 3) exceeded these values, and therefore the set goals were not achieved. Any refinement of the calculation of these performance goals (for example, by using true intraindividual variation rather than reference ranges, which themselves include analytical variation) is likely to make the goals even more stringent.
The conclusion that must be drawn from these results is that at normal amino acid concentrations, analytical performance as revealed by the EQA scheme is inadequate and at subnormal concentrations will be even less satisfactory. On the other hand, when amino acids are grossly increased, as in some untreated inherited metabolic disorders, the analytical performance of amino acid quantification is likely to be adequate as long as the amino acids in question are correctly identified.
